Gavreto
Payments companies reported to CMS as associated with Gavreto. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Gavreto, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Gavreto
These are the largest totals companies reported as associated with Gavreto. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joseph Bailes | Mckinney, TX | $64,000.00 | |
| Mark Frohlich | Seattle, WA | Medical Oncology | $41,310.11 |
| Binay Shah | Sequim, WA | Hematology & Oncology | $26,000.00 |
| Courtney Dinardo | Houston, TX | Hematology & Oncology | $6,509.97 |
| Andrew Lassman | New York, NY | Neurology (Psychiatry & Neurology) | $4,550.00 |
| Hetty Carraway | Chagrin Falls, OH | Hematology & Oncology | $3,987.50 |
| Vivek Subbiah | Houston, TX | Pediatric Hematology-Oncology | $3,517.31 |
| Rishi Sawhney | Pleasanton, CA | Medical Oncology | $3,217.00 |
| Mark Socinski | Orlando, FL | Hematology & Oncology | $3,059.13 |
| Joshua Zeidner | Chapel Hill, NC | Hematology & Oncology | $2,901.36 |
Prescribed Gavreto?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.